[Edaily Starin YUN GI BACK Reporter] The “2026 Korea Grand Music Awards” (2026 KGMA) has unveiled its second lineup, featuring solo artists, bands, and trot performers. (Photo courtesy of the KGMA Organizing Committee) The KGMA Organizing Committee announced on the 7th that 10 acts—including Dayoung, Minho, Young K, Yuna, Choi Ye-na, Lucy, Touched, Nobelbright, Park Ji-hyun, and Jang Min-ho—will take the stage at the “2026 KGMA.” This lineup spans a wide range of genres, from solo artists to bands and trot singers. Dayoung, Minho, Young K, Yuna, and Choi Ye-na will perform solo sets, while Lucy, Touched, and the Japanese band Novelbright will also join the lineup. In the trot category, Park Ji-hyun and Jang Min-ho have been named. The first lineup, revealed earlier, included RISE, Ahop, ANDBLE, ATEEZ, All Day Project, CRAVITY, Close Your Eyes, KIKI, TREASURE, and Hearts to Hearts. The organizing committee plans to reveal the third and fourth lineups sequentially in the future. The “2026 KGMA” will take place on November 7–8 at Gocheok Sky Dome in Guro-gu, Seoul. On the first day, Risen’s Won-i and actress Nam Ji-hyun will serve as MCs, while on the second day, IVE’s Liz and actor Kim Jae-won will take the helm. The awards ceremony is set to be a festival featuring artists who have achieved success over the past year across various genres of popular music, including K-pop, rock, and trot. It will be broadcast live on ENA, and details regarding domestic and international OTT streaming platforms will be announced at a later date.
This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…